KRAS and pancreatic neoplasm: Notably, among the eight evaluable patients with pancreatic tumors in FIGHT-207, seven patients had FGFR fusions in the context of the KRAS wild-type background, highlighting the importance of testing for FGFR2 fusions in this population with few therapeutic options.